Caribou Biosciences, Inc.
CRBU · NASDAQ
Company research
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company headquartered in Berkeley, California, dedicated to developing transformative genome-edited allogeneic, or off-the-shelf, cell therapies for patients with devastating diseases, including hematologic malignancies, autoimmune diseases, and solid tumors. Co-founded in 2011 by Nobel laureate Jennifer Doudna, the company leverages its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) technology platform to engineer next-generation CAR-T and CAR-NK cell therapies with superior precision and enhanced disease-fighting activity. Its clinical pipeline includes CB-010 (anti-CD19 CAR-T for B cell non-Hodgkin lymphoma and autoimmune diseases), CB-011 (anti-BCMA CAR-T for multiple myeloma), and CB-012 (anti-CD371 CAR-T for acute myeloid leukemia), alongside CB-020, a CAR-NK cell therapy targeting solid tumors. The company also holds a collaboration agreement with AbbVie and maintains licenses to foundational CRISPR intellectual property from the University of California, reinforcing its position at the forefront of genome engineering and cell therapy innovation.
Research reports
This report dissects CRBU’s historical financials and describes the company as in a precarious position typical of a clinical-stage biotech, with zero product revenue, steep and worsening net losses, very negative margins, and a quarterly cash burn around the high‑tens of millions that shortens its runway to roughly 1.5 years. While noting a still-strong cash balance and low leverage, it concludes that continuous cash outflows, dependence on new funding, and lack of commercial revenue make the equity unattractive and extremely high risk at this stage.
KoalaGains · November 5, 2025Caribou Biosciences, Inc. (CRBU) Future Performance Analysis (2026)KoalaGains models CRBU’s long-term prospects entirely around its early-stage allogeneic CAR‑T pipeline and chRDNA gene-editing platform, contrasting a blue-sky scenario of successful CB‑010/CB‑011 data, partnerships, and eventual high revenue growth with a bear case of complete pipeline failure. It emphasizes that the company is years behind leading CRISPR peers, has no product revenue, requires additional financing by mid‑2026, and faces intense competition, so the probability‑weighted outlook is weak even though upside could be dramatic for very risk‑tolerant investors if the platform is validated.
OpeoAI · November 3, 2025CRBU Investment Analysis Report 11/03/2025This AI‑generated investment report combines technicals, sentiment, news flow, and fundamentals for CRBU, finding short‑term technical momentum improving (MACD crossover, RSI in the 60s, active catalysts) but a long‑term downtrend with the share price still well below the 200‑day moving average. After an extended bull–bear debate around upcoming ANTLER and CaMMouflage trial readouts, small‑cap volatility, negative earnings, and dependence on clinical and regulatory milestones, it recommends a hold stance and argues investors should wait for clearer validation before taking a strong directional position.